Shanghai Sinorda Pharmaceutical Technology

Shanghai Sinorda Pharmaceutical Technology is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, dedicated to the discovery and development of innovative small molecule therapeutics. The company primarily focuses on oncology and metabolic diseases, with a pipeline of proprietary candidates designed to address significant unmet medical needs. Its lead programs include selective inhibitors targeting FGFR and RET for the treatment of various solid tumors, as well as a URAT1 inhibitor for hyperuricemia and gout. Sinorda maintains an integrated R&D platform that spans from early-stage drug discovery to clinical development.